Glioblastoma is the most aggressive and most common malignant brain cancer in adults. It is currently treated with surgery, ...

After three years since announcing his initial diagnosis, San Francisco Symphony Music Director Laureate Michael Tilson ...

On his website, conductor and composer Michael Tilson Thomas announced he would “wind down my public appearances” over the next two months.

Michael Tilson Thomas' brain tumor has returned, and the 80-year-old conductor intends to lead his final performance in April ...

Michael Tilson Thomas has announced the imminent end of his conducting career. The 80-year-old musician, who disclosed a diagnosis of cancer in 2021, will cease performing after concerts scheduled for ...

HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a ...

Michael Tilson Thomas, who led the San Francisco Symphony for 25 years, said, “Now is the time to wind down my public ...

Furthermore, they have demonstrated that it is possible to reprogram other cancer cells to become dependent on this enzyme – ...

Window of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent ...

About the 6th Glioblastoma Drug Development Summit The 6th Glioblastoma Drug Development Summit is the only industry-led event bringing together 90+ experts from pharma, biotech, neuro-oncology ...

The research on glioblastoma requires the development of new preclinical murine models. The GL261 cell line forms glioma-like tumors in a reliable manner when transplanted intracranially, but these ...

CNS Pharmaceuticals (CNSP) will present at the 6th Glioblastoma Drug Development Summit being held February 18-20, 2025 in Boston, MA. As part ...